US 11,168,058 B2 | MANUFACTURE OF A CRYSTALLINE PHARMACEUTICAL PRODUCT

Please sign up or log in to access the advanced features of
Ex Parte Enterprise.

or Log in

General

US 11,168,058 B2

MANUFACTURE OF A CRYSTALLINE PHARMACEUTICAL PRODUCT

Tech Center:

1600 Biotechnology and Organic Chemistry

Examiner:

Karen Cheng

Art Unit:

1626 Organic Chemistry

Agent:

Finnegan, Henderson, Farabow, Garrett & Dunner, LLP

Inventors:

Merja REUNANEN; Anna STAFFANS

Assignee:

ORION CORPORATION

Priority:

02/27/18

Filed:

09/06/19

Granted:

11/09/21

Expiration:

02/27/38

Abstract

The present disclosure relates to crystalline particles of N—((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)-propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide (I) having specific surface area (SSA) in the range from about 8 to about 16 m2/g, preferably from about 10 to about 15 m2/g, and to the method for the preparation of such particles. Compound (I) is a potent androgen receptor (AR) modulator which is useful as a medicament for example in the treatment of prostate cancer.

General

Analytics

Cases

Patent Assignments

Citations